Market PotentialAnalyst believes AVERSA Fentanyl can be the first abuse-deterrent transdermal fentanyl patch, which could lead to taking market share from the current generic transdermal patches.
PartnershipsNutriband has a partnership with Kindeva Drug Delivery, formerly part of 3M, to add the AVERSA technology to Kindeva’s transdermal fentanyl patch.
Regulatory PathwayAnalysts believe the Phase 1 clinical trial will show sufficient abuse deterrence for Nutriband to file a New Drug Application using the 505(b)(2) pathway for approval.